J. Henri Bayle
Chief Tech/Sci/R&D Officer presso BELLICUM PHARMACEUTICALS, INC.
Posizioni attive di J. Henri Bayle
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2014 | - |
Storia della carriera di J. Henri Bayle
Formazione di J. Henri Bayle
| University of Alberta | Undergraduate Degree |
| Princeton University | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 3 |
| Canada | 2 |
Posizioni
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Settori
| Consumer Services | 3 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 1 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
- Borsa valori
- Insiders
- J. Henri Bayle
- Esperienza
